Urogen Pharma Ltd (URGN): Oppenheimer Keeps Buy Rating Today, Has a Target of $75.0000/Share

May 16, 2018 - By Kurt Siggers

Urogen Pharma Ltd (URGN) Rating Reaffirmed

Recently, In a report revealed to clients on Tuesday, 15 May, Urogen Pharma Ltd (URGN) shares have had their Buy Rating reiterated by stock analysts at Oppenheimer, who currently has a $75.0000 TP on company. This target by Oppenheimer means the possibile upside of 19.33 % from the last stock close price.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Coverage

Among 4 analysts covering Urogen Pharma Ltd (URGN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Urogen Pharma Ltd has $65.0 highest and $62.0 lowest target. $63.67’s average target is 1.31% above currents $62.849 stock price. Urogen Pharma Ltd had 5 analyst reports since March 15, 2018 according to SRatingsIntel. Oppenheimer maintained the shares of URGN in report on Tuesday, April 3 with “Buy” rating. Ladenburg maintained UroGen Pharma Ltd. (NASDAQ:URGN) rating on Friday, March 16. Ladenburg has “Buy” rating and $65.0 target. Oppenheimer maintained the stock with “Buy” rating in Thursday, March 15 report. On Wednesday, April 4 the stock rating was upgraded by Raymond James to “Buy”. The rating was maintained by Jefferies with “Buy” on Friday, March 16.

The stock increased 4.50% or $2.709 during the last trading session, reaching $62.849. About 77,680 shares traded. UroGen Pharma Ltd. (URGN) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $972.53 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It currently has negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

More notable recent UroGen Pharma Ltd. (NASDAQ:URGN) news were published by: Nasdaq.com which released: “UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments” on May 15, 2018, also Seekingalpha.com with their article: “Key events next week – healthcare” published on May 11, 2018, Globes.Co.Il published: “Nasdaq exec: 5 Israeli cos set for IPOs” on May 15, 2018. More interesting news about UroGen Pharma Ltd. (NASDAQ:URGN) were released by: Nasdaq.com and their article: “UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018” published on May 08, 2018 as well as Globenewswire.com‘s news article titled: “UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell” with publication date: April 24, 2018.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.